AZD 4547

Drug Profile

AZD 4547

Alternative Names: AZD4547

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; National Cancer Institute (USA); University of Glasgow
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • Phase II Breast cancer; Gastric cancer; Lung cancer; Oesophageal cancer
  • Phase I/II Glioblastoma; Solid tumours
  • Phase I Bladder cancer

Most Recent Events

  • 16 Jan 2017 AstraZeneca terminates the phase II SHINE trial in Gastric and Oesophageal cancer (Second-line therapy, Late-stage disease) in United Kingdom, Belgium, Bulgaria, Canada, France, Hungary, India, Italy, Japan, South Korea, Romania, Spain, Taiwan, Ukraine, Germany, Czech Republic (NCT01457846)
  • 01 Oct 2016 Phase-I clinical trials in Bladder cancer (Second-line therapy or greater) in USA (PO) (NCT02546661)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top